Regenacy Pharmaceuticals
Regenacy Pharmaceuticals is a clinical-stage biopharma developing ricolinostat, a first-in-class HDAC6 inhibitor, as a disease-modifying treatment for painful diabetic peripheral neuropathy, targeting diabetic neuropathy patients with plans to expand into China.
- Company typePrivate
- Founded2016
- HeadquartersWaltham, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Regenacy Pharmaceuticals firmographics
Firmographics- Name
- Regenacy Pharmaceuticals
- Legal name
- Regenacy Pharmaceuticals, Inc.
- Website
- https://regenacy.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Regenacy Pharmaceuticals is a clinical-stage biopharma developing ricolinostat, a first-in-class HDAC6 inhibitor, as a disease-modifying treatment for painful diabetic peripheral neuropathy, targeting diabetic neuropathy patients with plans to expand into China.
- Ownership category
- akta.pro rank
Regenacy Pharmaceuticals industry classification
Industry- Product category
- Peripheral Neuropathy Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Regenacy Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Markets served
Regenacy Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Development and Commercialization: Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the sale of prescription pharmaceutical products following regulatory approval. The company is developing ricolinostat as a treatment for peripheral neuropathies with plans to commercialize upon successful clinical trials and regulatory clearance.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Regenacy Pharmaceuticals product offering
Product offeringCore offering
Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing ricolinostat, a selective HDAC6 inhibitor drug candidate, as a potential first-in-class treatment for painful diabetic peripheral neuropathy (DPN). The product targets the underlying pathology of peripheral neuropathies rather than just symptomatic relief, and is being advanced through Phase 2 clinical trials with plans for international expansion including China markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Ricolinostat
Companies that use Regenacy Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Regenacy Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Regenacy Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
Regenacy Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Global biopharma with established neuropathic pain assets (e.g., pregabalin/Lyrica history) and broad diabetes pipeline; competes with Regenacy in the same neuropathy treatment space via both approved products and ongoing R&D.
- Eli Lilly: Major biopharmaceutical company with a large diabetes franchise (dulaglutide/trulicity) and significant R&D presence in diabetic complications including DPN, making it both a potential competitor and a natural acquirer of neuropathy assets like ricolinostat.
- Daiichi Sankyo: Japanese global biopharma with strong Asia-Pacific commercial infrastructure and a neuropathy/pain franchise; comparable both as a potential competitor and as a natural strategic partner for a US-Japan cross-border clinical asset.
- Astellas Pharma: Japanese global biopharma with active programs in diabetic complications and neurology; operates in the same therapeutic space and provides a natural regional commercialization partner for a US-developed neuropathy asset.
Direct peers
- Applied Therapeutics: Clinical-stage biopharma developing mechanism-driven therapies for diabetic complications and rare diseases; similar in size, stage, and focus on high-unmet-need diabetic indications, making it a directly comparable small-cap peer.
- Novaremed: Clinical-stage company developing a non-opioid therapy (NRD.E1) for painful diabetic peripheral neuropathy; a directly comparable small-cap peer targeting the same indication with a novel mechanism and similar development stage.
- Lexicon Pharmaceuticals: Clinical-stage biopharma developing mechanism-driven therapies, with a history of programs in diabetic complications and neuropathic pain; a directly comparable small-cap peer with overlapping therapeutic area focus.
Emerging players
- Viva Biotech: Asia-based discovery and development services/investor with biopharma incubation; comparable as both an investor in the same asset class and as an emerging player in the regional biopharma ecosystem in which Regenacy's syndicate operates.
- Chromocell: Clinical-stage biotech developing novel therapeutics for pain and sensory disorders, including neuropathic pain; comparable in stage, scale, and therapeutic focus to Regenacy's single-asset DPN program.
- Clexio Biosciences: Clinical-stage company developing therapies for neuropathic pain and other neurological conditions; similar in size and stage, and competing for the same patient population and payer attention as Regenacy.
Market position
Customer concentration
Regenacy Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regenacy Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Regenacy Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regenacy Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regenacy Pharmaceuticals
What does Regenacy Pharmaceuticals do?
Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing ricolinostat, a selective HDAC6 inhibitor drug candidate, as a potential first-in-class treatment for painful diabetic peripheral neuropathy (DPN). The product targets the underlying pathology of peripheral neuropathies rather than just symptomatic relief, and is being advanced through Phase 2 clinical trials with plans for international expansion including China markets.
Is Regenacy Pharmaceuticals a public or private company?
Regenacy Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Regenacy Pharmaceuticals founded?
Regenacy Pharmaceuticals was founded in 2016. It employs 1 to 10 people.
Where is Regenacy Pharmaceuticals based?
Regenacy Pharmaceuticals is headquartered in Waltham, United States, in the North America region.
How does Regenacy Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Development and Commercialization.
Who are Regenacy Pharmaceuticals's main competitors?
Broad incumbents on record are Pfizer, Eli Lilly, Daiichi Sankyo and Astellas Pharma. Direct peers are Applied Therapeutics, Novaremed and Lexicon Pharmaceuticals. Emerging players are Viva Biotech, Chromocell and Clexio Biosciences.
Does Regenacy Pharmaceuticals have an API?
No public API is recorded for Regenacy Pharmaceuticals.
What industry is Regenacy Pharmaceuticals in?
Regenacy Pharmaceuticals's product category is Peripheral Neuropathy Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.